Assessment of Tool Placement in Pulmonary Nodule(s) Using a Robotic Navigational Bronchoscopy System

Lung Cancer Clinical Trial

Official title:

A Prospective Investigation to Assess the Accurate Tool Placement in Pulmonary Nodule(s) Using a Robotic Navigational Bronchoscopy System With Adjunct Real-time Imaging

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05867953
• Other study ID #: ISI-ION-EU1-2022
• Status: Active, not recruiting
• Phase: N/A
• Start date: April 20, 2023
• Est. completion date: May 31, 2025

Study information

• Verified date: May 2024
• Source: Intuitive Surgical
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this research study is to evaluate the effectiveness of the ION endoluminal system at reaching and obtaining biopsies from lung nodules when used in combination with 3-dimensional imaging such as CT scans. Data on safety will also be collected.

Description:

This is a prospective, interventional, multicentre, single arm study which will be conducted in Europe and will involve up to 200 patients undergoing a pulmonary nodule biopsy using the Ion Endoluminal System in conjunction with 3D imaging. The objectives of the study are focused on evaluating the procedure characteristics of the pulmonary nodule biopsy procedure, including rate of tool in nodule, diagnostic accuracy, sensitivity for malignancy and safety. All subjects will be followed up at 1 week and 1 month after the procedure. If the biopsy did not provide a diagnosis or did not show cancer and was still under observation at the 1 month visit, then they will have further follow up at 6 months. Similarly, if the status is unchanged (non-malignant diagnosis) at 6 months, the patients a 13 months visit should be completed.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 200
• Est. completion date: May 31, 2025
• Est. primary completion date: April 11, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patient is aged 18 years or older at time of consent.

2. Patient is suitable for elective nodule biopsy via bronchoscopy under general anesthesia per Investigator's discretion.

3. Patient has solid or semi-solid pulmonary nodule(s) of =6 mm and =3 cm in largest dimension (based on pre-procedure CT scan).

4. Pulmonary nodule(s) intended for biopsy during the study procedure is (are) located at least 4 (=4) airway generations out (trachea = generation 0, e.g. subsegmental bronchi or beyond) based on pre-procedure CT scan.

5. Patient has a moderate to high risk of lung cancer based on clinical, demographic, and radiologic information or with suspected metastatic disease. High risk for malignancy patients are eligible if a biopsy is required or requested prior to intervention.

6. Patient is willing and able to give written informed consent for Clinical Investigation participation.

7. Patient is not legally incapacitated or in a legal/court ordered institution.

Exclusion Criteria:

1. Patient has a lack of fitness or exercise capacity to undergo bronchoscopy under general anesthesia as determined by Investigator prior to procedure.

2. Patient with type 1 pure ground glass opacity target nodule(s) intended for biopsy during study procedure.

3. Presence of mediastinal or hilar lymphadenopathy requiring tissue biopsy on pre-procedure CT or positron emission tomography (PET)-CT scan.

4. Patient with American Society of Anesthesiologists Classification (ASA) =4.

5. Patient underwent a pneumonectomy.

6. Any invasive concomitant procedure not related to the pulmonary nodule(s) or suspected disease state.

7. Female patient of child-bearing potential who is unable to take adequate contraceptive precautions or is known to be pregnant, and/or breast feeding.

8. Patient has a documented medical history of uncorrectable coagulopathy, bleeding, or platelet disorder.

9. Patient is taking antiplatelet or anticoagulant medications that cannot be stopped per standard practice.

10. Patient is currently participating or has participated in another Clinical Investigation within the past 30 days, such as interventional trials or trials with experimental agents or agents of unknown risk, that may affect the endpoints of this Clinical Investigation.

11. Investigator, in their professional opinion, has decided that it is in the patient's best interest to not participate in the Clinical Investigation.

12. Patient is not willing to comply with post study procedure participation requirements.

Related Conditions & MeSH terms

• Lung Cancer
• Multiple Pulmonary Nodules

Intervention

Device:
• Biopsy with the Robotic- Ion Endoluminal System with Adjunct Real-time Imaging
Biopsy with the Robotic- Navigational Bronchoscopy System with Adjunct Real-time Imaging

Locations

Country	Name	City	State
United Kingdom	Barts Health Nhs Trust	London
United Kingdom	Royal Brompton & Harefield Hospitals, Part of Guy'S and St Thomas' Nhs Foundation Trust	London

Sponsors (1)

Lead Sponsor	Collaborator
Intuitive Surgical

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Rate of procedure-related Adverse Events through 30 days post-procedure	The study's safety endpoint is the rate of procedure-related Adverse Events through 30 days post-procedure	30 days
Other	Exploratory endpoint 1: Procedure-related characteristics	Procedure time (from catheter inserted into the patient's airways to catheter removed from the patient's airways) will be reported.	At time of the biopsy procedure (Day 0)
Other	Exploratory endpoint 2:rEBUS visualization characteristics	The frequency of rEBUS visualization view during the biopsy will be summarized.	At time of the biopsy procedure (Day 0)
Other	Exploratory endpoint 3: Biopsy workflow	The sequence of biopsy tools used will be summarized.	At time of the biopsy procedure (Day 0)
Primary	Tool in Nodule	Rate of achieving biopsy tool position within the targeted nodule(s), documented by means of intraprocedural 3D imaging.; Defined as how often the biopsy needle used to sample the tissue is positioned directly within the nodule before the sample is taken.; If biopsy forceps are used, it is how often the instrument is surrounding the nodule before the sample is taken	At time of the biopsy procedure (Day 0)
Secondary	Diagnostic accuracy of sample(s) obtained	Diagnostic accuracy will be calculated as the rate of diagnosis made using samples obtained during the study procedure (true positives and true negatives) relative to the number of cases performed.; Diagnostic yield may also be reported in conjunction with diagnostic accuracy and calculated as the rate of malignant and benign diagnosis made relative to the number of cases performed; non-diagnostic samples will not be included in the numerator.	Up to 13 months post procedure
Secondary	Sensitivity for malignancy of sample(s) obtained	Sensitivity for malignancy of samples is assessed as the number of subjects with a malignant condition determined through the study procedure (true positives) relative to the number of subjects with an underlying malignant disease state (true positives + false negatives). The subjects underlying disease state will be determined by follow-up diagnostic interventions or treatment decisions/interventions, and/or radiographic follow-up.	Up to 13 months post procedure